Immunotherapy Trial Design
Cross-source consensus on Immunotherapy Trial Design from 1 sources and 4 claims.
1 sources · 4 claims
Uses
Evidence quality
Highlighted claims
- Future validation should prospectively test the macrophage M0 signature in neoadjuvant immunotherapy trials. — Predictive radiomics for evaluation of cancer immune SignaturE in glioblastoma: the PRECISE-GBM study
- The study positions MRI-based immune profiling as a potential enrichment tool for neoadjuvant immunotherapy trials. — Predictive radiomics for evaluation of cancer immune SignaturE in glioblastoma: the PRECISE-GBM study
- Candidate macrophage-directed approaches include CSF-1/CSF1R inhibition, TLR agonists, oncolytic viral therapies, checkpoint inhibitors, cytokine therapies, and anti-CD47 therapy. — Predictive radiomics for evaluation of cancer immune SignaturE in glioblastoma: the PRECISE-GBM study
- Macrophage M0 results were discussed in relation to therapies that target or reprogram macrophage biology. — Predictive radiomics for evaluation of cancer immune SignaturE in glioblastoma: the PRECISE-GBM study